AcelRx announces top-line data from Phase 3 study of Sufentanil NanoTab AcelRx Pharmaceuticals announced top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System. Top-line results of the Phase 3 clinical trial demonstrate that the Sufentanil NanoTab PCA System was non-inferior to intravenous patient-controlled analgesia with morphine for the primary endpoint of Patient Global Assessment of method of pain control over the 48-hour study period as determined by the combined percentage of patients with PGA ratings of "good" or "excellent".
News For ACRX From The Last 14 Days
Check below for free stories on ACRX the last two weeks.
AcelRx reports Q4 adjusted EPS (18c), consensus (17c) Reports Q4 revenue $27.6M, may not compare to consensus $4.93M. During the fourth quarter of 2013, AcelRx received a $30M upfront payment from Grunenthal GmbH associated with the Zalviso commercialization agreement in the EU and Australia, of which $27.4M was recognized as revenue in the quarter.